Digital The future of R&D innovation Alexander Gray and Mike Rea from IDEA Pharma explain why the current pharma R&D model is broken, and how it’s hindering commercialisation for companies across the industry
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.